Editas achieves in vivo preclinical proof of concept for sickle cell; seeks partner for reni-cel

Editas Medicine, Inc.

Achieved 29% HSPC editing and 20% HbF-expressing red blood cells in humanized mice after single dose using proprietary tLNP.
Initiated process to partner or out-license reni-cel; engaged Moelis & Company to lead global process.
Q3 2024 cash, equivalents, and marketable securities ~$265M; ~$320M after $57M upfront from DRI Healthcare.
On track to present substantive RUBY trial SCD data at ASH December 2024; EdiTHAL data by year-end 2024.
Company will not host Q3 2024 earnings call; strategic update webinar held October 22, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.